Please assess the completion status of the following clinical trial:

Trial Title: ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ADA-SCID with no HLA-identical sibling donor available~* pediatric age and at least one of the following criteria:~* inadequate immune response after PEG-ADA for \> 6 months~* patients who discontinued PEG-ADA due to intolerance, allergy or auto-immunity~* patients for whom enzyme replacement therapy is not a life long therapeutic option~Exclusion Criteria:~* HIV infection~* history or current malignancy~* Patients who received a previous gene therapy treatment in the 12 months prior to receiving Strimvelis~* any other conditions dangerous for the patients according to the investigator

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Gene Therapy (Type: EXPERIMENTAL): Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan

Based on this trial design, predict the completion outcome and termination type (if applicable).